CD274 and ovarian cancer: Given low response rates to ICIs for the treatment of ovarian cancer (9, 10), testing ICIs targeting the PD-1/PD-L1 blockade, alone or in combination with other strategies, in these models may help to stratify those women who may respond to treatment.